Alcon: Glaucoma, Open-Angle trials

The registry lists 121 Glaucoma, Open-Angle studies with Alcon as lead sponsor. 1 are open to participants now and 56 have results posted.

Phase 1 2Phase 2 38Phase 3 44Phase 4 26No phase 15(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Hydrus® Microstent New Enrollment Post-Approval StudyRecruitingNCT04553523Not applicable
• Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-StentCompletedNCT04629521Not applicableResults posted
• Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedNCT04620135Phase 3Results posted
• Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in JapanCompletedNCT03844945Phase 2Results posted
• Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world SettingCompletedNCT03808688Phase 4Results posted
• Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular HypertensionCompletedNCT03310580Phase 2Results posted
• Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular HypertensionCompletedNCT03284853Phase 3Results posted
• Post Approval Study of the CyPass SystemTerminatedNCT03273907Not applicableResults posted
• Hydrus Microstent for Refractory Open-Angle GlaucomaCompletedNCT03267134Not applicableResults posted
• Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)CompletedNCT03233308Phase 2Results posted
• Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic SolutionCompletedNCT02874846Phase 2Results posted
• A Three Part Study of MGV354 in Ocular Hypertension or GlaucomaCompletedNCT02743780Phase 1/2Results posted
• Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®TerminatedNCT02730871Phase 4Results posted
• A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS TrialCompletedNCT02700984Not applicableResults posted
• Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular HypertensionCompletedNCT02674854Phase 3Results posted
• Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionCompletedNCT02558400Phase 3Results posted
• Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular HypertensionCompletedNCT02558374Phase 3Results posted
• SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)CompletedNCT02419508Phase 4Results posted
• Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)CompletedNCT02339584Phase 3Results posted
• Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular HypertensionCompletedNCT02207621Phase 3Results posted
• Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionCompletedNCT02207491Phase 3Results posted
• 6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT02140060Phase 2Results posted
• Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular PressureCompletedNCT02057575Phase 2Results posted
• Comparing Hydrus Microstent(TM) to the iStent for Lowering IOP in Glaucoma Patients Undergoing Cataract SurgeryCompletedNCT02024464Not applicableResults posted
• Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic EyesCompletedNCT02023242Not applicableResults posted
• Efficacy of Travoprost/Timolol for Uncontrolled Intraocular PressureCompletedNCT02003391Phase 4Results posted
• Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT01978600Phase 4Results posted
• Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin AnalogueCompletedNCT01937312Phase 4Results posted
• Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®CompletedNCT01937299Phase 4Results posted
• Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular PressureCompletedNCT01731002Phase 2Results posted
• Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)CompletedNCT01539239Not applicableResults posted
• Study of AR-13324 in Patients With Elevated Intraocular PressureCompletedNCT01528787Phase 2Results posted
• Efficacy of Changing to TRAVATAN® From Prior TherapyCompletedNCT01510145Phase 4Results posted
• Efficacy of Changing to TRAVATAN® From Prior TherapyCompletedNCT01493427Phase 4Results posted
• Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)CompletedNCT01464424Phase 4Results posted
• Travoprost 3-Month Safety and Efficacy StudyCompletedNCT01453855Phase 3Results posted
• A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%CompletedNCT01426867Phase 2Results posted
• Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in CanadaCompletedNCT01415401Phase 4Results posted
• Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular HypertensionCompletedNCT01357616Phase 3Results posted
• Patient Preference Comparison of AZARGA Versus COSOPTCompletedNCT01340014Phase 4Results posted
• Efficacy of Changing to DUOTRAV® From Prior TherapyCompletedNCT01327599Phase 4Results posted
• Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionCompletedNCT01310777Phase 3Results posted
• Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionCompletedNCT01309204Phase 3Results posted
• Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%CompletedNCT01297920Phase 3Results posted
• Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%CompletedNCT01297517Phase 3Results posted
• Travoprost Five Day Posology StudyCompletedNCT01114893Phase 2Results posted
• Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular HypertensionCompletedNCT00966940Phase 4Results posted
• Safety and Efficacy of Brinzolamide/Brimonidine Fixed CombinationTerminatedNCT00961649Phase 2Results posted
• Efficacy Study of Travoprost APS Versus TRAVATANCompletedNCT00848536Phase 3Results posted
• Examination of Ocular Surface Effects With Administration of Travatan Z and XALATANCompletedNCT00798759Phase 4Results posted
• Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular HypertensionCompletedNCT00763061Phase 4Results posted
• Phase III Clinical Trial of TRAVATAN Z in Ocular Surface HealthCompletedNCT00761319Phase 3Results posted
• Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00690794Phase 3Results posted
• A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00527592Phase 4Results posted
• Adherence Assessment With Travalert Dosing AidCompletedNCT00508469Phase 4Results posted
• Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular HypertensionTerminatedNCT00471068Phase 4Results posted
• A Long-term Safety Study of Once-daily TravatanCompletedNCT00051168Phase 3Results posted
• Reformulated PG324 Ophthalmic Solution for Intraocular Pressure ReductionCompletedNCT07082816Phase 3
• Next Generation RocklatanCompletedNCT06441643Phase 2
• Safety and Effectiveness of the Hydrus MicrostentTerminatedNCT05198297Not applicable
• Safety and Efficacy Study of the Hydrus Aqueous Implant in Subjects With POAGCompletedNCT03065036Phase 1/2
• Safety and Efficacy Trial to Evaluate the Hydrus(TM) Implant in Subjects Undergoing Cataract Surgery.CompletedNCT01818115Not applicable
• A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 DaysCompletedNCT01789736Phase 2
• A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 MonthsCompletedNCT01699464Phase 2
• Travacom Post Marketing Surveillance StudyWithdrawnNCT01510132Phase 4
• A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic SolutionTerminatedNCT01485822
• Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%WithdrawnNCT01452009Phase 3
• 24-hour Efficacy of AR-12286CompletedNCT01330979Phase 2
• AL-54478 Proof of Concept StudyCompletedNCT01318252Phase 2
• Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412CTerminatedNCT01312454Phase 2
• Divided Dose of TRAVATAN®CompletedNCT01298687Phase 2
• ELAZOP Switching Study in KoreaCompletedNCT01055366Phase 4
• Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00928590Phase 3
• DuoTrav APS Versus XALACOM® in Ocular Surface HealthTerminatedNCT00912054Phase 3
• Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface HealthCompletedNCT00892762Phase 3
• Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00872651Phase 3
• Safety and Efficacy Study of DuoTrav APS Versus DuoTravWithdrawnNCT00862472Phase 3
• DuoTrav® Eye Drops As Replacement Therapy ProgramCompletedNCT00828906Phase 4
• A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular HypertensionTerminatedNCT00788541Phase 2
• Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00761709Phase 2
• Safety and Efficacy of Travoprost/Timolol BAC-freeCompletedNCT00760539Phase 3
• Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular HypertensionCompletedNCT00759239Phase 4
• A Multi-Dose Study With a Treatment for Open-Angle GlaucomaWithdrawnNCT00705770Phase 2/3
• Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00691717Phase 2/3
• Collection of Blood Specimens From Patients in AL-3789 Studies for Elevated Intraocular Pressure (IOP)CompletedNCT00691639
• Glaucoma Adherence Study, SpainCompletedNCT00680329
• Glaucoma Adherence StudyCompletedNCT00676637
• A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00672997Phase 3
• Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00670033Phase 2
• 24 Hour IOP Lowering Efficacy of AL-3789CompletedNCT00643669Phase 2
• Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose TravoprostCompletedNCT00637130Phase 2
• Adjunctive Study of AL-37807 Ophthalmic SuspensionCompletedNCT00620256Phase 2
• IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00527501Phase 2
• A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular HypertensionCompletedNCT00465803Phase 3
• Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00465621Phase 2
• Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle GlaucomaCompletedNCT00451152Phase 2
• A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00372931Phase 2
• Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular HypertensionCompletedNCT00372827Phase 4
• A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00326092Phase 2
• Anecortave Acetate in Patients With Open-angle GlaucomaCompletedNCT00320203Phase 2